Cargando…

Entecavir downregulates interleukin-37 in patients with chronic active hepatitis B infection

OBJECTIVES: Interleukin-37 (IL-37) has been identified as a potent inhibitor of the immune response. This study aimed to examine IL-37 expression in patients with chronic active hepatitis B (CAHB), and explore its possible regulatory role during inflammation. METHODS: Peripheral blood mononuclear ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meng, Jiang-Ping, Luo, Peng, Bai, Yao, Cui, Fang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Retrospective Clinical Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254606/ https://www.ncbi.nlm.nih.gov/pubmed/31939340 http://dx.doi.org/10.1177/0300060519884157

Ejemplares similares

Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy
por: Lin, Tien-Ching, et al.
Publicado: (2018)

Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients
por: Lai, Rui-Min, et al.
Publicado: (2023)

Baseline metabolites could predict responders with hepatitis B virus-related liver fibrosis for entecavir or combined with FuzhengHuayu tablet
por: Dai, Yun-Kai, et al.
Publicado: (2023)

Correlation Between Serum Entecavir Concentration and Virological Response in Patients with Chronic Type B Hepatitis
por: Wu, Zhengjie, et al.
Publicado: (2019)

The role of entecavir in the treatment of chronic hepatitis B
por: Dimou, Evangelini, et al.
Publicado: (2007)

Comparable efficacy with entecavir monotherapy and tenofovir–entecavir combination in chronic hepatitis B patients
por: Baqai, Sumbella, et al.
Publicado: (2015)

Entecavir-based combination therapies for chronic hepatitis B: A meta-analysis
por: Luo, Aoran, et al.
Publicado: (2018)

Safety and efficacy of entecavir for the treatment of chronic hepatitis B
por: Osborn, Melissa
Publicado: (2011)

Dupilumab in patients with chronic hepatitis B on concomitant entecavir
por: Ly, Karen, et al.
Publicado: (2019)

Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B
por: Ahn, Sang Hoon, et al.
Publicado: (2013)

On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B
por: Gao, Yu-Hua, et al.
Publicado: (2016)

High levels of serum interleukin-6 increase mortality of hepatitis B virus-associated acute-on-chronic liver failure
por: Zhou, Chao, et al.
Publicado: (2020)

Efficacy of Entecavir therapy in elderly patients with chronic hepatitis B infection
por: Tan, You-wen, et al.
Publicado: (2014)

Thyroid dysfunction is associated with the loss of hepatitis B surface antigen in patients with chronic hepatitis B undergoing treatment with α-interferon
por: Luo, Wenfan, et al.
Publicado: (2021)

Efficacy of Lamivudine or Entecavir on Acute Exacerbation of Chronic Hepatitis B
por: Kanda, Tatsuo, et al.
Publicado: (2011)

Entecavir and lamivudine therapy for severe acute chronic hepatitis B
por: LIU, CHANGHONG, et al.
Publicado: (2013)

Clinical utility of entecavir for chronic hepatitis B in Chinese patients
por: Wang, Jiyao
Publicado: (2013)

Add-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with Entecavir
por: Tamai, Hideyuki, et al.
Publicado: (2017)

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
por: Itokawa, Norio, et al.
Publicado: (2020)

One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C
por: Xu, Jing-Hang, et al.
Publicado: (2022)

Association between Hepatic Steatosis and Entecavir Treatment Failure in Chinese Patients with Chronic Hepatitis B
por: Jin, Xi, et al.
Publicado: (2012)

Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B
por: Lee, Jaemin, et al.
Publicado: (2016)

Seroconversion of Hepatitis B Virus Surface Antigen in Chronic Hepatitis B Child Treated with Entecavir
por: Li, Dong, et al.
Publicado: (2012)

Entecavir and Hepatitis B Immune Globulin in Patients Undergoing Liver Transplantation for Chronic Hepatitis B
por: Perrillo, Robert, et al.
Publicado: (2013)

Severe Acute Hepatitis B Treated With Entecavir.
por: De Socio, Giuseppe Vittorio Luigi, et al.
Publicado: (2011)

Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir
por: Choi, Han Na, et al.
Publicado: (2015)

Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir
por: Kim, David Sooik, et al.
Publicado: (2019)

Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy
por: Huang, Chih-Wen, et al.
Publicado: (2023)

Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy
por: WANG, YANG, et al.
Publicado: (2016)

Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA
por: Kim, Dong Hyun, et al.
Publicado: (2017)

Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B
por: Peng, Cheng-Yuan, et al.
Publicado: (2017)

Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine
por: Cai, Shaohang, et al.
Publicado: (2017)

Value of gamma-glutamyltranspeptidase-to-platelet ratio in diagnosis of hepatic fibrosis in patients with chronic hepatitis B
por: Hu, Yan-Chao, et al.
Publicado: (2017)

Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients
por: Shang, Jin, et al.
Publicado: (2021)

Predictors of inflammatory activity in treatment-naive hepatitis B e-antigen-negative patients with chronic hepatitis B infection
por: Hu, Jianhua, et al.
Publicado: (2020)

Seroconversion of Hepatitis B Envelope Antigen (HBeAg) by Entecavir in a Child with Chronic Hepatitis B
por: Hasosah, Mohammed Y., et al.
Publicado: (2012)

Safety of entecavir antiviral therapyduring an accidental pregnancy in patients with chronic hepatitis B
por: Cao, Lihua, et al.
Publicado: (2023)

Effect of Additional Clostridium butyricum on the Intestinal Flora of Chronic Hepatitis B Patients Treated with Entecavir
por: Lu, Yu-Xia, et al.
Publicado: (2021)

Incidence of infectious complications is associated with a high mortality in patients with hepatitis B virus-related acute-on-chronic liver failure
por: Wang, Chen, et al.
Publicado: (2019)

Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B
por: Chang, Te-Sheng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h8penhnolilud6b0hlh15kjroo